|
Ark Therapeutics is loading its boat with therapies that target cancer and vascular disease. The biotech company has one product on the market in the UK and the US -- Kerraboot, a wound dressing that treats chronic leg and foot ulcers. Lead candidate Cerepro has shown promise in extending the lives of brain tumor patients. And it has two other clinical-stage candidates that may treat cancer-related muscle wasting and prevent blood vessels from blocking after vascular graft surgery. The firm develops and markets its own products in key markets, such as Europe and the US; it largely develops drugs for indications where it has a good chance of getting the regulatory privileges of Fast Track or Orphan Drug status.
|
| | | Contact Information | |
Address: |
79 New Cavendish St.
London W1W 6XB, United Kingdom
| | Phone: | +44-20-7388-7722 | | Fax: | +44-20-7388-7805 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 1.30 M | | Revenue Growth (1 yr): | (-40.10%) |
|
|
Key People
| | • |
CEO:
Nigel Parker
| | • |
CFO and Company Secretary:
Martyn D. Williams
| | • |
Technical Director:
Robert Shaw
|
|
|
